Starling Oncology Warrant
STLNW
12 hedge funds and large institutions have $7.36M invested in Starling Oncology Warrant in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
9% more funds holding
Funds holding: 11 → 12 (+1)
0.21% more ownership
Funds ownership: 4.58% → 4.79% (+0.21%)
4% less capital invested
Capital invested by funds: $7.67M → $7.36M (-$307K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$66K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$7.05K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$10.4K |
STLNW Hedge Fund Activity: Q3 2022 in Review
12 of the 5,829 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q3 2022, worth a combined $7.36M — down 4% from $7.67M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new STLNW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Man Group, opening a new position worth an estimated $66K. The largest seller was Wolverine Asset Management, cutting an estimated $10.4K.
- 12 institutional investors held Starling Oncology Warrant (STLNW) as of Q3 2022, up from 11 in Q2 2022.
- Funds reported $7.36M of Starling Oncology Warrant stock for Q3 2022, down 4% quarter-over-quarter.
- 1 fund opened new Starling Oncology Warrant positions in Q3 2022 and 0 closed out, a net change of +1 holder.
- The largest Starling Oncology Warrant buyer in Q3 2022 was Man Group, an estimated $66K added.
- The largest Starling Oncology Warrant seller in Q3 2022 was Wolverine Asset Management, an estimated $10.4K sold.
Based on aggregated 13F filings for Q3 2022.